Novartis’ canakinumab fails to meet primary endpoint in CAN-COVID trial

This article was originally published here

CAN-COVID is a randomised, double-blind and placebo-controlled study designed to evaluate the efficacy and safety of canakinumab plus standard of care (SoC) in hospitalised patients with Covid-19 pneumonia

The post Novartis’ canakinumab fails to meet primary endpoint in CAN-COVID trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply